Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720–1748. https://doi.org/10.1038/s41375-022-01620-2

Article  PubMed  PubMed Central  Google Scholar 

Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 36:1703–1719. https://doi.org/10.1038/s41375-022-01613-1

Article  PubMed  PubMed Central  Google Scholar 

Giné E, Martinez A, Villamor N et al (2010) Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 95:1526–1533. https://doi.org/10.3324/haematol.2010.022277

Article  CAS  PubMed  PubMed Central  Google Scholar 

El Hussein S, Khoury JD, Medeiros LJ (2021) B-prolymphocytic leukemia: is it time to retire this entity? Ann Diagn Pathol 54:151790. https://doi.org/10.1016/j.anndiagpath.2021.151790

Article  PubMed  Google Scholar 

Siebert R, Schuh A, Ott G et al (2023) Response to the comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH) on the 5th edition of the world health organization classification of haematolymphoid tumors. Leukemia 37:1170–1172. https://doi.org/10.1038/s41375-023-01872-6

Article  PubMed  PubMed Central  Google Scholar 

Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377:1331–1344. https://doi.org/10.1056/NEJMoa1614598

Article  CAS  PubMed  Google Scholar 

Hiddemann W, Barbui AM, Canales MA et al (2018) Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 36:2395–2404. https://doi.org/10.1200/JCO.2017.76.8960

Article  CAS  PubMed  Google Scholar 

Rimsza LM, Li H, Braziel RM et al (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151–e153. https://doi.org/10.3324/haematol.2017.175059

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morschhauser F, Fowler NH, Feugier P et al (2018) Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 379:934–947. https://doi.org/10.1056/NEJMoa1805104

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bachy E, Seymour JF, Feugier P et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 37:2815–2824. https://doi.org/10.1200/JCO.19.01073

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zamò A, Gerhard-Hartmann E, Ott G et al (2022) Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series. Virchows Arch 481:935–943. https://doi.org/10.1007/s00428-022-03420-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nann D, Ramis-Zaldivar JE, Müller I et al (2020) Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. Blood Adv 4:5652–5665. https://doi.org/10.1182/bloodadvances.2020002944

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidt J, Gong S, Marafioti T et al (2016) Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood 128:1101–1111. https://doi.org/10.1182/blood-2016-03-703819

Article  CAS  PubMed  PubMed Central  Google Scholar 

El Behery R, Laurini JA, Weisenburger DD et al (2018) Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphoma. Hum Pathol 72:180–190. https://doi.org/10.1016/j.humpath.2017.11.002

Article  PubMed  Google Scholar 

Laurent C, Adélaïde J, Guille A et al (2021) High-grade follicular lymphomas exhibit clinicopathologic, cytogenetic, and molecular diversity extending beyond grades 3A and 3B. Am J Surg Pathol 45:1324–1336. https://doi.org/10.1097/PAS.0000000000001726

Article  PubMed  Google Scholar 

Li S, Young KH, Medeiros LJ (2018) Diffuse large B-cell lymphoma. Pathology 50:74–87. https://doi.org/10.1016/j.pathol.2017.09.006

Article  PubMed  Google Scholar 

Pasqualucci L, Dalla-Favera R (2018) Genetics of diffuse large B-cell lymphoma. Blood 131:2307–2319. https://doi.org/10.1182/blood-2017-11-764332

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282. https://doi.org/10.1182/blood-2003-05-1545

Article  CAS  PubMed  Google Scholar 

Runge HFP, Lacy S, Barrans S et al (2021) Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL). Br J Haematol 192:216–220. https://doi.org/10.1111/bjh.17132

Article  PubMed  Google Scholar 

Scott DW, Wright GW, Williams PM et al (2014) Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123:1214–1217. https://doi.org/10.1182/blood-2013-11-536433

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chapuy B, Stewart C, Dunford AJ et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679–690. https://doi.org/10.1038/s41591-018-0016-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wright GW, Da Huang W, Phelan JD et al (2020) A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37:551-568.e14. https://doi.org/10.1016/j.ccell.2020.03.015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salaverria I, Philipp C, Oschlies I et al (2011) Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 118:139–147. https://doi.org/10.1182/blood-2011-01-330795

Article  CAS  PubMed  Google Scholar 

Ramis-Zaldivar JE, Gonzalez-Farré B, Balagué O et al (2020) Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood 135:274–286. https://doi.org/10.1182/blood.2019002699

Article  PubMed  PubMed Central  Google Scholar 

Salaverria I, Martin-Guerrero I, Wagener R et al (2014) A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood 123:1187–1198. https://doi.org/10.1182/blood-2013-06-507996

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horn H, Kalmbach S, Wagener R et al (2021) A diagnostic approach to the identification of Burkitt-like lymphoma with 11q aberration in aggressive B-cell lymphomas. Am J Surg Pathol 45:356–364. https://doi.org/10.1097/PAS.0000000000001613

Article  PubMed  Google Scholar